By Bhanvi Satija and Manas Mishra (Reuters) – Healthcare conglomerate Johnson & Johnson on Tuesday raised the midpoint of its full-year earnings forecast by 10 cents despite beating first-qu[...]
Read more
Health
Eli Lilly to invest additional $1.6 billion in 2 new plants
(Reuters) – Eli Lilly and Co said on Monday it will invest an additional $1.6 billion at its two new manufacturing sites in Indiana, United States to support the manufacturing of its recently ap[...]
Read more
US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent
By Blake Brittain WASHINGTON (Reuters) -The U.S. Supreme Court on Monday declined to hear Novartis Pharmaceuticals Corp’s bid to revive a key patent on its blockbuster multiple sclerosis drug Gi[...]
Read more
Juul, Altria settle with Minnesota over teen vaping addiction
By Brendan Pierson (Reuters) – E-cigarette company Juul Labs Inc and its former largest investor, Marlboro maker Altria Group Inc, on Monday settled claims by the state of Minnesota that they fu[...]
Read more
HSBC shareholder Ping An to vote for bank’s break-up at annual meeting -source
HONG KONG/LONDON (Reuters) – HSBC’s biggest shareholder Ping An is likely to vote in favour of splitting the bank up at its annual investor meeting on May 5, a source familiar with the Chi[...]
Read more
Merck to take $10.3 billion R&D charge for Prometheus deal this year
(Reuters) – Merck & Co expects a research-and-development charge of about $10.3 billion, or $4 per share, this year as the drugmaker accounts its deal for Prometheus Biosciences Inc as an as[...]
Read more
US Supreme Court spurns Sanofi appeal to revive EpiPen suit against Viatris
By John Kruzel WASHINGTON (Reuters) -The U.S. Supreme Court on Monday declined to hear a bid by Sanofi SA to revive its antitrust lawsuit accusing rival pharmaceutical company Viatris Inc of illegally[...]
Read more
Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return
By Julie Steenhuysen and Michael Erman (Reuters) – An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin can[...]
Read more
Catalent flags problems at its manufacturing plants; CFO departs
(Reuters) – Contract drug manufacturer Catalent Inc on Friday warned that slow production at three of its facilities will impact its fiscal 2023 results and said CFO Thomas Castellano has steppe[...]
Read more